BPS Bioscience, Inc. Announces NSD1 and NSD2 Profiling Kits

SAN DIEGO - July 15, 2013 - PRLog -- BPS Bioscience, Inc. (BPS) is excited to announce the release of assay kits for both NSD1 and NSD2.  NSD (Nuclear SET Domain-containing protein) 1 and 2 are histone methyltransferase enzymes that act as transcriptional regulators.  NSD1 and NSD2 (also known as WHSC1 and MMSET) specifically methylate lysine 36 of histone H3 and lysine 20 of histone H4. Disregulation of NSD activity can cause several severe growth disorders, including Sotos syndrome and Beckwith-Wiedemann syndrome (NSD1) or Wolf-Hirschhorn syndrome (NSD2).  NSD overexpression has also been linked to several human cancers; NSD1 mutations have been linked to acute myeloid leukemia and lung cancer, while rearrangements in the NSD2 gene are associated with prostate cancer and have been found in over 15% of multiple myelomas.

Because of their important roles in the regulation of normal growth and development and in oncogenesis, the NSD proteins are of high interest as targets for small molecule drug development.  Recognizing this need, BPS has developed chemiluminescent assay kits for high throughput inhibitor screening of both NSD1 and NSD2.  These are the first assays commercially available for NSD activity determination.  BPS also offers recombinant active NSD1 and NSD2 enzymes as well as screening and profiling services to identify inhibitors of NSD1, NSD2, and 16 other methyltransferase enzymes.  The newly added research tools complement the broad array of epigenetic proteins, kits, and custom biochemical services already offered by BPS.

To learn more about BPS Bioscience’s methyltransferase enzymes and assay kits, please visit http://bpsbioscience.com/methyltransferase, and to learn more about all of the methyltransferase services BPS offers please visit http://www.bpsbioscience.com/images/Flyers/HMT_profiling_services.pdf

About BPS Bioscience, Inc.

Headquartered in San Diego, California, BPS Bioscience, Inc. is a leading manufacturer of Histone Methyltransferases, as well as Acetyltransferases, Bromodomains, Cytokines, HDACs, Histone Demethylases, Kinases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases (PARPs), Proteases, Ubiquitin Enzymes, Methyl-lysine Readers and Metabolic Enzymes.  BPS offers one of the largest selections of recombinant enzymes and assay kits for drug discovery and continues to expand its portfolio of innovative drug discovery products.  BPS also provides custom protein expression, biochemical and cell based assays, and compound screening and profiling services.  BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide.  By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases.  Visit BPS’s website for more information: http://www.bpsbioscience.com.